JPMorgan Chase & Co. Purchases 811,349 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

JPMorgan Chase & Co. increased its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 288,736.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 811,630 shares of the biotechnology company's stock after purchasing an additional 811,349 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.04% of CytomX Therapeutics worth $836,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Monimus Capital Management LP purchased a new position in CytomX Therapeutics during the fourth quarter valued at $375,000. Virtu Financial LLC bought a new stake in CytomX Therapeutics during the third quarter worth about $104,000. Geode Capital Management LLC grew its holdings in CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company's stock worth $948,000 after purchasing an additional 34,032 shares during the period. Traphagen Investment Advisors LLC bought a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $31,000. Finally, Prudential Financial Inc. lifted its holdings in shares of CytomX Therapeutics by 76.2% during the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 27,800 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Performance

Shares of CTMX stock traded up $0.04 during mid-day trading on Friday, hitting $0.80. The company's stock had a trading volume of 1,417,226 shares, compared to its average volume of 1,792,243. The stock has a market cap of $64.66 million, a price-to-earnings ratio of 4.72 and a beta of 1.11. CytomX Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $4.94. The business has a 50-day moving average price of $0.63 and a 200 day moving average price of $0.86.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.45. The business had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Equities research analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CTMX has been the subject of a number of analyst reports. Piper Sandler started coverage on CytomX Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $2.50 price objective for the company. StockNews.com started coverage on CytomX Therapeutics in a report on Tuesday, April 15th. They set a "hold" rating for the company. Wedbush reiterated an "outperform" rating and issued a $5.00 price target on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, HC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $4.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.